Please ensure Javascript is enabled for purposes of website accessibility

World Health Organization Says COVID-19 Confirmed Fatality Rate Is 3.4%

By Eric Volkman - Updated Mar 5, 2020 at 9:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The World Health Organization gave context around its confirmed fatality rate for the rapidly-spreading illness.

Editor's Note: This article was updated to reflect that the WHO shared confirmed fatality rate -- not mortality rate.

The World Health Organization (WHO) on Tuesday said the confirmed fatality rate of COVID-19, the disease caused by SARS-CoV-2 remained at 3.4%.

WHO Director-General Tedros Adhanom Ghebreyesus described SARS-CoV-2 as "a unique virus, with unique features. This virus is not influenza. We are in uncharted territory."


Image source: Getty Images

Numerous comparisons have been made between influenza -- aka, the flu -- and COVID-19. They share similar symptoms, and both spread rapidly among populations. Influenza, however, is far less deadly, with a confirmed fatality rate of only 0.1%.

The coronavirus continues to spread. In the U.S., according to the latest figures, there are 149 confirmed cases. On Wednesday, the 11th U.S. fatality was reported -- an elderly person in Placer County, California. Meanwhile, the second case on the East Coast has been confirmed -- an unidentified man who commuted to work in Manhattan from his home in neighboring Westchester County, New York.

Against this backdrop, more pharmaceutical companies and biotechs continue to join the fight. On Wednesday, Alnylam Pharmaceuticals (ALNY -2.03%) and Vir Biotechnology (VIR -0.90%) announced they will expand their partnership and attempt to jointly develop treatments for SARS-CoV-2. That project will center on RNA interference therapeutics. Alnylam and Vir have been collaborating on other treatments since 2017.

Shares of Alnylam and Vir both closed notably higher on Wednesday, with the former increasing by just over 5% and the latter by nearly 10%. The S&P 500 closed the day 4.2% higher.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$129.58 (-2.03%) $-2.69
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$24.14 (-0.90%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.